The increasingly human and profitable monoclonal antibody market
File(s)manuscript_final_accepted.pdf (154.5 KB)
Accepted version
Author(s)
Martins De Jesus Lima Grilo, A
Mantalaris, Athanasios
Type
Journal Article
Abstract
The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.
Date Issued
2019-01-31
Date Acceptance
2018-06-23
Citation
Trends in Biotechnology, 2019, 37 (1), pp.9-16
ISSN
0167-7799
Publisher
Elsevier
Start Page
9
End Page
16
Journal / Book Title
Trends in Biotechnology
Volume
37
Issue
1
Copyright Statement
© 2018 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
European Commission
Grant Number
European Commission
Subjects
Science & Technology
Life Sciences & Biomedicine
Biotechnology & Applied Microbiology
biosimilars
market analysis
monoclonal antibody
06 Biological Sciences
09 Engineering
10 Technology
Biotechnology
Publication Status
Published
Date Publish Online
2018-06-23